Crossmark

Radiofrequency Ablation for Early Stage Breast Cancer as a Potential Alternative to Partial Mastectomy: 5-Year Results from the Multiple-Center, Single-Arm, Phase 3 RAFAELO Study (NCCH1409)

Crossref DOI link: https://doi.org/10.1245/s10434-026-19220-0

Published Online: 2026-02-18

Published Print: 2026-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kinoshita, Takayuki

Takayama, Shin

Fujisawa, Tomomi

Watanabe, Kenichi

Yamamoto, Naohito

Shien, Tadahiko

Ito, Mitsuya

Takahashi, Mina

Futamura, Manabu

Onishi, Tatsuya

Yoshida, Masayuki

Takahashi, Masato

Doihara, Hiroyoshi

Yorikane, Eiko

Ohata, Keiko

Machida, Ryunosuke

Tsuda, Hitoshi

,

Kinoshita, Takayuki

Takayama, Shin

Fujisawa, Tomomi

Watanabe, Kenichi

Yamamoto, Naohito

Shien, Tadahiko

Ito, Mitsuya

Takahashi, Mina

Futamura, Manabu

Onishi, Tatsuya

Tsuda, Hitoshi
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (JP16lk0201029)

Japan Agency for Medical Research and Development (JP19ck0106318)

Japan Agency for Medical Research and Development (JP23ck0106590)
License Information

Text and Data Mining valid from 2026-02-18

Version of Record valid from 2026-02-18
More Information

Article History

Received: 28 October 2025

Accepted: 25 January 2026

First Online: 18 February 2026

Disclosure

: Kenichi Watanabe reports relevant financial activities outside the submitted work at Chugai, Eli Lilly, Nippon-Kayaku, Kyowa-Kirin, Novartis, Taiho, Eisai, Pfizer, Shionogi, Daiichi-Sankyo, and AstraZeneca. Masayuki Yoshida reports honorarium from Covidien Japan.

Document is current

Any future updates will be listed below